In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cyclacel Pharmaceuticals, Inc.

http://www.cyclacel.com

Latest From Cyclacel Pharmaceuticals, Inc.

Alentis Aims To Put The Brakes On Fibrosis

Building on 20 years of work and positive preclinical data, and backed by a fresh injection of cash, Alentis is taking its liver fibrosis candidate into Phase I trials in the fourth quarter.

Financing Liver & Hepatic

Finance Watch: Two New VC Funds Target Early Stage And Beyond

Private Company Edition: venBio’s new fund plus Ysios Capital’s recent €216m ($260m) fund adds up to $810m in fresh venture capital for life science companies. Also, Nikang and Esco attracted $200m each in VC investment, Pulmocide closed a $92m series C round and Stablix launched with $63m. 

Financing Innovation

Finance Watch: 14 Biopharma Companies Raise $1bn From VC, Canadian Government

Private Company Edition: More $100m-plus mega-rounds means another billion-dollar week for venture capital deals, including financings for G2 Bio, Hummingbird and Numab. Also, BioTheryX brings in $92m, Vedere launches with $77m and Eliem raises $60m two months after launching with $80m. 

Finance Watch Innovation

The Drugs That Could Face US Generic/Biosimilar Competition In 2021

Other expected generics include Viatris' Perforomist (formoterol fumarate), Pfizer's Sutent (sunitinib), Sanofi's Jevtana (cabazitaxel) and possibly Boehringer Ingelheim's Pradaxa.

Biosimilars Generic Drugs
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Xcyte Therapies
    • ALIGN Pharmaceuticals
UsernamePublicRestriction

Register